Limits...
Pharmacological and non-pharmacological recanalization strategies in acute ischemic stroke.

Frendl A, Csiba L - Front Neurol (2011)

Bottom Line: Newer generation thrombolytic agents (alteplase, pro-urokinase, reteplase, tenecteplase, desmoteplase) have shorter half-life and are more fibrin-specific.Only alteplase has Food and Drug Administration (FDA) approval for the treatment of acute stroke (1996).Stenting can also be an option in case of acute internal carotid artery occlusion in the future.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, University of Debrecen Medical and Health Science Center Debrecen, Hungary.

ABSTRACT
According to the guidelines of the European Stroke Organization (ESO) and the American Stroke Association (ASA), acute stroke patients should be managed at stroke units that include well organized pre- and in-hospital care. In ischemic stroke the restoration of blood flow has to occur within a limited time window that is accomplished by fibrinolytic therapy. Newer generation thrombolytic agents (alteplase, pro-urokinase, reteplase, tenecteplase, desmoteplase) have shorter half-life and are more fibrin-specific. Only alteplase has Food and Drug Administration (FDA) approval for the treatment of acute stroke (1996). The National Institute of Neurological Disorders and Stroke (NINDS) trial proved that alteplase was effective in all subtypes of ischemic strokes within the first 3 h. In the European cooperative acute stroke study III trial, intravenous (IV) alteplase therapy was found to be safe and effective (with some restrictions) if applied within the first 3-4.5 h. In middle cerebral artery (MCA) occlusion additional transcranial Doppler insonication may improve the breakdown of the blood clot. According to the ESO and ASA guidelines, intra-arterial (IA) thrombolysis is an option for recanalization within 6 h of MCA occlusion. Further trials on the IA therapy are needed, as previous studies have involved relatively small number of patients (compared to IV trials) and the optimal IA dose of alteplase has not been determined (20-30 mg is used most commonly in 2 h). Patients undergoing combined (IV + IA) thrombolysis had significantly better outcome than the placebo group or the IV therapy alone in the NINDS trial (Interventional Management of Stroke trials). If thrombolysis fails or it is contraindicated, mechanical devices [e.g., mechanical embolus removal in cerebral ischemia (MERCI)- approved in 2004] might be used to remove the occluding clot. Stenting can also be an option in case of acute internal carotid artery occlusion in the future. An intra-aortic balloon was used to increase the collateral blood flow in the Safety and Efficacy of NeuroFlo(™) Technology in Ischemic Stroke trial (results are under evaluation). Currently, there is no approved effective neuroprotective drug.

No MeSH data available.


Related in: MedlinePlus

Patients who are alert and have a stable cardio-respiratory status must be transferred to the CT directly. Unstable patients should receive emergency therapy first. If the thrombolysis cannot be done due to the results of imaging or other criteria, the patient must be transferred to the stroke unit. If thrombolysis is not contraindicated according to the imaging, it must be started as soon as possible. All acute stroke patients should be treated in stroke unit regardless whether they have already received thrombolysis or not.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3105226&req=5

Figure 2: Patients who are alert and have a stable cardio-respiratory status must be transferred to the CT directly. Unstable patients should receive emergency therapy first. If the thrombolysis cannot be done due to the results of imaging or other criteria, the patient must be transferred to the stroke unit. If thrombolysis is not contraindicated according to the imaging, it must be started as soon as possible. All acute stroke patients should be treated in stroke unit regardless whether they have already received thrombolysis or not.

Mentions: Alert patients with stable cardio-respiratory status should be transferred directly to the CT. The neurological examination and blood sampling should be performed at the radiology (CT) area to save time (Figure 2)


Pharmacological and non-pharmacological recanalization strategies in acute ischemic stroke.

Frendl A, Csiba L - Front Neurol (2011)

Patients who are alert and have a stable cardio-respiratory status must be transferred to the CT directly. Unstable patients should receive emergency therapy first. If the thrombolysis cannot be done due to the results of imaging or other criteria, the patient must be transferred to the stroke unit. If thrombolysis is not contraindicated according to the imaging, it must be started as soon as possible. All acute stroke patients should be treated in stroke unit regardless whether they have already received thrombolysis or not.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3105226&req=5

Figure 2: Patients who are alert and have a stable cardio-respiratory status must be transferred to the CT directly. Unstable patients should receive emergency therapy first. If the thrombolysis cannot be done due to the results of imaging or other criteria, the patient must be transferred to the stroke unit. If thrombolysis is not contraindicated according to the imaging, it must be started as soon as possible. All acute stroke patients should be treated in stroke unit regardless whether they have already received thrombolysis or not.
Mentions: Alert patients with stable cardio-respiratory status should be transferred directly to the CT. The neurological examination and blood sampling should be performed at the radiology (CT) area to save time (Figure 2)

Bottom Line: Newer generation thrombolytic agents (alteplase, pro-urokinase, reteplase, tenecteplase, desmoteplase) have shorter half-life and are more fibrin-specific.Only alteplase has Food and Drug Administration (FDA) approval for the treatment of acute stroke (1996).Stenting can also be an option in case of acute internal carotid artery occlusion in the future.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, University of Debrecen Medical and Health Science Center Debrecen, Hungary.

ABSTRACT
According to the guidelines of the European Stroke Organization (ESO) and the American Stroke Association (ASA), acute stroke patients should be managed at stroke units that include well organized pre- and in-hospital care. In ischemic stroke the restoration of blood flow has to occur within a limited time window that is accomplished by fibrinolytic therapy. Newer generation thrombolytic agents (alteplase, pro-urokinase, reteplase, tenecteplase, desmoteplase) have shorter half-life and are more fibrin-specific. Only alteplase has Food and Drug Administration (FDA) approval for the treatment of acute stroke (1996). The National Institute of Neurological Disorders and Stroke (NINDS) trial proved that alteplase was effective in all subtypes of ischemic strokes within the first 3 h. In the European cooperative acute stroke study III trial, intravenous (IV) alteplase therapy was found to be safe and effective (with some restrictions) if applied within the first 3-4.5 h. In middle cerebral artery (MCA) occlusion additional transcranial Doppler insonication may improve the breakdown of the blood clot. According to the ESO and ASA guidelines, intra-arterial (IA) thrombolysis is an option for recanalization within 6 h of MCA occlusion. Further trials on the IA therapy are needed, as previous studies have involved relatively small number of patients (compared to IV trials) and the optimal IA dose of alteplase has not been determined (20-30 mg is used most commonly in 2 h). Patients undergoing combined (IV + IA) thrombolysis had significantly better outcome than the placebo group or the IV therapy alone in the NINDS trial (Interventional Management of Stroke trials). If thrombolysis fails or it is contraindicated, mechanical devices [e.g., mechanical embolus removal in cerebral ischemia (MERCI)- approved in 2004] might be used to remove the occluding clot. Stenting can also be an option in case of acute internal carotid artery occlusion in the future. An intra-aortic balloon was used to increase the collateral blood flow in the Safety and Efficacy of NeuroFlo(™) Technology in Ischemic Stroke trial (results are under evaluation). Currently, there is no approved effective neuroprotective drug.

No MeSH data available.


Related in: MedlinePlus